Live Breaking News & Updates on உயிர் அறிவியல் கனடியன்
Stay updated with breaking news from உயிர் அறிவியல் கனடியன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras News provided by Share this article Share this article LAVAL, QC, and CAMBRIDGE, England, Dec. 15, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ( Liminal BioSciences or the Company ), a clinical-stage biopharmaceutical company, today announced that the first subject has been dosed in the Company s fezagepras Phase 1 multiple ascending dose clinical trial in healthy volunteers. The new clinical trial is designed to look at more frequent daily dosing (twice and three times daily) of fezagepras up to 2,400mg for a total of 14 days. The clinical trial is a standard placebo-controlled Phase 1 ascending dose design in healthy volunteers. The clinical trial endpoints will include safety, pharmacokinetics, and exploratory biomarkers related to the mechanism of action of fezagepras. The data from this clinical trial will be used to guide se ....